Astrazeneca Vaccine Cost
- All
- News
- Videos
-
No Evidence Of Increased Blood Clot Risk From Vaccine, Says AstraZeneca
AstraZeneca Plc said on Sunday a review of safety data of people vaccinated with its COVID-19 vaccine has shown no evidence of an increased risk of blood clots.
-
"Happy New Year, All Risks Paid Off": Adar Poonawalla On Vaccine Approval
All the risks taken by Serum Institute have finally paid off, tweeted Adar Poonawalla, the chief executive of the Pune-based vaccine manufacturer, shortly after the country's drug regulator cleared its Covishield vaccine for emergency approval in India.Mr Poonawalla reiteratedthat the Covishieldvaccine -- developed by Serum Institute of India in pa...
-
Serum Institute Likely To Supply Covid Vaccine At Rs 250 Per Dose: Report
Serum Institute of India, the world's largest vaccine producer by volume, is close to signing a supply contract with the Centre and likely to fix prices at Rs 250 ($3.39) per dose of the vaccine, Business Standard reported on Tuesday, citing people familiar with the matter.
-
AstraZeneca Promises Virus Vaccine At Cost Price Worldwide
Hopes of an effective vaccine against coronavirus becoming available rose again on Monday with AstraZeneca and Oxford University claiming success with their product, becoming the third team to do so.
-
"Delighted," Says Adar Poonawalla On Oxford's Vaccine Announcement
As AstraZeneca reported on Monday that its COVID-19 vaccine could be around 90% effective without any serious side effects, Adar Poonawalla, whose Serum Institute is producing the shot in India said he was "delighted". He said the low cost vaccine would soon be widely available.
-
No Evidence Of Increased Blood Clot Risk From Vaccine, Says AstraZeneca
AstraZeneca Plc said on Sunday a review of safety data of people vaccinated with its COVID-19 vaccine has shown no evidence of an increased risk of blood clots.
-
"Happy New Year, All Risks Paid Off": Adar Poonawalla On Vaccine Approval
All the risks taken by Serum Institute have finally paid off, tweeted Adar Poonawalla, the chief executive of the Pune-based vaccine manufacturer, shortly after the country's drug regulator cleared its Covishield vaccine for emergency approval in India.Mr Poonawalla reiteratedthat the Covishieldvaccine -- developed by Serum Institute of India in pa...
-
Serum Institute Likely To Supply Covid Vaccine At Rs 250 Per Dose: Report
Serum Institute of India, the world's largest vaccine producer by volume, is close to signing a supply contract with the Centre and likely to fix prices at Rs 250 ($3.39) per dose of the vaccine, Business Standard reported on Tuesday, citing people familiar with the matter.
-
AstraZeneca Promises Virus Vaccine At Cost Price Worldwide
Hopes of an effective vaccine against coronavirus becoming available rose again on Monday with AstraZeneca and Oxford University claiming success with their product, becoming the third team to do so.
-
"Delighted," Says Adar Poonawalla On Oxford's Vaccine Announcement
As AstraZeneca reported on Monday that its COVID-19 vaccine could be around 90% effective without any serious side effects, Adar Poonawalla, whose Serum Institute is producing the shot in India said he was "delighted". He said the low cost vaccine would soon be widely available.
